Company Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Krivoshik
PSD | President | - | - |
Morten Sogaard
COO | Chief Operating Officer | - | 22-04-30 |
Jason Schwartz
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-31 |
David Smethurst
LAW | General Counsel | - | 21-07-31 |
Fulvio Mavilio
PRN | Corporate Officer/Principal | - | 17-07-17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kush Parmar
BRD | Director/Board Member | 42 | 13-06-30 |
Alan Beggs
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,783,265 | 42,304,829 ( 92.40 %) | 0 | 92.40 % |
Company contact information
Astellas Gene Therapies, Inc.
600 California Street 17th floor
94108, San Francisco
+415 818 1001
http://www.astellasgenetherapies.comSector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |